Abivertinib in patients with T790M ‐positive advanced NSCLC and its subsequent treatment with osimertinib
ConclusionsAbivertinib is a unique novel third ‐generation EGFR TKI with good tolerance and efficacy in EGFR T790M(+) NSCLC patients. For patients with progressive disease after treatment with abivertinib, osimertinib could be an option for subsequent therapy but further studies are required.Key points
Abivertinib is a novel third ‐generation EGFR TKI targeting theEGFR T790M mutation
Abivertinib is well tolerated and efficacious in T790M ‐positive patients
Abivertinib has a unique structure, efficacy, and resistance mechanism compared with osimertinib
Osimertinib treatment after AC0010 showed a good response
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Hanping Wang,
Ruili Pan,
Xiaotong Zhang,
Xiaoyan Si,
Mengzhao Wang,
Li Zhang Tags: ORIGINAL ARTICLE Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Men | Non-Small Cell Lung Cancer | Oral Cancer | Study